Bevacizumab (Avastin) doubles risk of GI adverse events in ovarian cancer trial. @MedReporter reports. http://bit.ly/fJtPMS
1:31 PM - 10 Mar 2011
0 replies
1 retweet
0 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.